Latest News

From tax deduction to first-time insurance buyers to nudging vehicle owners to buy third-party vehicle insurance, Budget 2024 can announce sops to achieve the vision of universal insurance coverage.

Read More

​ From tax deduction to first-time insurance buyers to nudging vehicle owners to buy third-party vehicle insurance, Budget 2024 can announce sops to achieve the vision of universal insurance coverage. From tax deduction to first-time insurance buyers to nudging vehicle owners to buy third-party vehicle insurance, Budget 2024 can announce sops to achieve the vision of universal insurance coverage.  Moneycontrol Latest News Read More  

From tax deduction to first-time insurance buyers to nudging vehicle owners to buy third-party vehicle insurance, Budget 2024 can announce sops to achieve the vision of universal insurance coverage.

The yield on the 10-year sovereign note slipped to 2.48%, a level unseen since 2002.

Read More

​ The yield on the 10-year sovereign note slipped to 2.48%, a level unseen since 2002. The yield on the 10-year sovereign note slipped to 2.48%, a level unseen since 2002.  Moneycontrol Latest News Read More  

The yield on the 10-year sovereign note slipped to 2.48%, a level unseen since 2002.

Traders are advised to accumulate longs in Nifty with stop-loss of 21,500 on the closing basis.

Read More

​ Traders are advised to accumulate longs in Nifty with stop-loss of 21,500 on the closing basis. Traders are advised to accumulate longs in Nifty with stop-loss of 21,500 on the closing basis.  Moneycontrol Latest News Read More  

Traders are advised to accumulate longs in Nifty with stop-loss of 21,500 on the closing basis.

Reliance Industries has seen a decisive breakout of downward sloping resistance trendline adjoining highs of January 16 and January 20, and clocked 7 percent rally to end at record closing high of Rs 2,896.

Read More

​ Reliance Industries has seen a decisive breakout of downward sloping resistance trendline adjoining highs of January 16 and January 20, and clocked 7 percent rally to end at record closing high of Rs 2,896. Reliance Industries has seen a decisive breakout of downward sloping resistance trendline adjoining highs of January 16 and January 20, and clocked 7 percent rally to end at record closing high of Rs 2,896.  Moneycontrol Latest News Read More  

Reliance Industries has seen a decisive breakout of downward sloping resistance trendline adjoining highs of January 16 and January 20, and clocked 7 percent rally to end at record closing high of Rs 2,896.

Reliance Industries has seen a decisive breakout of downward sloping resistance trendline adjoining highs of January 16 and January 20, and clocked 7 percent rally to end at record closing high of Rs 2,896.

Read More

​ Reliance Industries has seen a decisive breakout of downward sloping resistance trendline adjoining highs of January 16 and January 20, and clocked 7 percent rally to end at record closing high of Rs 2,896. Reliance Industries has seen a decisive breakout of downward sloping resistance trendline adjoining highs of January 16 and January 20, and clocked 7 percent rally to end at record closing high of Rs 2,896.  Moneycontrol Latest News Read More  

Reliance Industries has seen a decisive breakout of downward sloping resistance trendline adjoining highs of January 16 and January 20, and clocked 7 percent rally to end at record closing high of Rs 2,896.

Julius Baer India continues to remain constructive on the Indian equity markets, driven by a continuation of momentum of the earnings cycle and strong domestic liquidity, coupled with the comeback of FPI flows.

Read More

​ Julius Baer India continues to remain constructive on the Indian equity markets, driven by a continuation of momentum of the earnings cycle and strong domestic liquidity, coupled with the comeback of FPI flows. Julius Baer India continues to remain constructive on the Indian equity markets, driven by a continuation of momentum of the earnings cycle and strong domestic liquidity, coupled with the comeback of FPI flows.  Moneycontrol Latest News Read More  

Julius Baer India continues to remain constructive on the Indian equity markets, driven by a continuation of momentum of the earnings cycle and strong domestic liquidity, coupled with the comeback of FPI flows.

All three major U.S. stock indexes advanced, with the tech-laden Nasdaq enjoying the largest percentage gain.

Read More

​ All three major U.S. stock indexes advanced, with the tech-laden Nasdaq enjoying the largest percentage gain. All three major U.S. stock indexes advanced, with the tech-laden Nasdaq enjoying the largest percentage gain.  Moneycontrol Latest News Read More  

All three major U.S. stock indexes advanced, with the tech-laden Nasdaq enjoying the largest percentage gain.

All three major U.S. stock indexes advanced, with the tech-laden Nasdaq enjoying the largest percentage gain.

Read More

​ All three major U.S. stock indexes advanced, with the tech-laden Nasdaq enjoying the largest percentage gain. All three major U.S. stock indexes advanced, with the tech-laden Nasdaq enjoying the largest percentage gain.  Moneycontrol Latest News Read More  

All three major U.S. stock indexes advanced, with the tech-laden Nasdaq enjoying the largest percentage gain.

The upcoming budget, being interim in nature, would likely be a non-event as far as big-bag announcements, new tax or spending pitches are concerned.

Read More

​ The upcoming budget, being interim in nature, would likely be a non-event as far as big-bag announcements, new tax or spending pitches are concerned. The upcoming budget, being interim in nature, would likely be a non-event as far as big-bag announcements, new tax or spending pitches are concerned.  Moneycontrol Latest News Read More  

The upcoming budget, being interim in nature, would likely be a non-event as far as big-bag announcements, new tax or spending pitches are concerned.

The U.S. Food and Drug Administration had given the company clearance last year to conduct its first trial to test its implant on humans.

Read More

​ The U.S. Food and Drug Administration had given the company clearance last year to conduct its first trial to test its implant on humans. The U.S. Food and Drug Administration had given the company clearance last year to conduct its first trial to test its implant on humans.  Moneycontrol Latest News Read More  

The U.S. Food and Drug Administration had given the company clearance last year to conduct its first trial to test its implant on humans.